Donepezil. A review of its use in Alzheimer's disease

Drugs and Aging

Volumn 16, Issue 3, 2000, Pages 199-226

  Dooley, Mukta ^a   Lamb, Harriet M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL;

ALZHEIMER DISEASE; ANOREXIA; CLINICAL TRIAL; COGNITION; COMMON COLD; CONFUSION; DAILY LIFE ACTIVITY; DIARRHEA; DRUG TOLERABILITY; FATIGUE; HUMAN; INSOMNIA; MUSCLE CRAMP; NAUSEA; PAIN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; URINARY TRACT INFECTION; VERTIGO; VOMITING;

EID: 0034022308     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200016030-00005     Document Type: Review

References (85)

1. 1. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 1997 May; 154 Suppl.: 1-39
2. 2. Herrmann N, Lanctôt KL, Naranjo CA. Behavioural disorders in demented elderly patients: current issues in pharmacotherapy. CNS Drugs 1996 Oct; 6: 280-300
3. 3. Foster RH, Plosker GL. Donepezil: pharmacoeconomic implications of therapy. Pharmacoeconomics 1999 Jul; 16: 99-114
4. 4. Hollister L, Gruber N. Drug treatment of Alzheimer's disease: effects on caregiver burden and patient quality of life. Drugs Aging 1996 Jan; 8: 47-55
5. 5. Steinberg M. Pharmacologic treatment of Alzheimer's disease: an update on approved, unapproved therapies. Formulary 1999 Jan; 34: 32-44
6. 6. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997 Oct 22-29; 278: 1363-71
7. 7. Shintani EY, Uchida KM. Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. Am J Health System Pharm 1997 Dec 15; 54: 2805-10
8. 8. Bryne GJA. Treatment of cognitive impairment in Alzheimer's disease. Aust J Hosp Pharm 1998 Aug; 28: 261-6
9. 9. Brodaty H. Realistic expectations for the management of Alzheimer's disease. Eur Neuropsychopharmacol 1999 Apr; 9 Suppl. 2: S43-52
10. 10. Early Identification of Alzheimer's Disease and Related Dementias Panel. Early identification of Alzheimer's disease and related dementias. Am Fam Physician 1997 Mar; 55: 1303-14
11. 11. Spencer CM, Noble S. Rivastigmine: a review of its use in Alzheimer's disease. Drugs Aging 1998 Nov; 13: 391-410
12. 12. Barner EL, Gray SL. Donepezil use in Alzheimer disease. Ann Pharmacother 1998 Jan; 32: 70-7
13. 13. Cutler NR, Sramek JJ. The role of bridging studies in the development of cholinestcrasc inhibitors for Alzheimer's disease. CNS Drugs 1998 Nov; 10: 355-64
14. 14. Doody RS. Clinical profile of donepezil in the treatment of Alzheimer's disease. Gerontology 1999; 45 Suppl. 1: 23-32
15. 15. Rogers SL. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil. Dementia Geriatr Cogn Disord 1998; 9 Suppl. 3: 29-42
16. 16. Schachter AS, Davis KL. Guidelines for the appropriate use of cholinesterase inhibitors in patients with Alzheimer's disease. CNS Drags 1999 Apr; 11: 281-8
17. 17. Lamy PP. The role of cholinesterase inhibitors in Alzheimer's disease. CNS Drugs 1994 Feb; 1: 146-65
18. 18. Sramek JJ, Cutler NR. Recent developments in the drug treatment of Alzheimer's disease. Drugs Aging 1999 May; 14: 359-73
19. 19. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial: the Donepezil Study Group. Dementia 1996 Nov-Dec; 7: 293-303
20. 20. Guillozet AL, Smiley JF, Mash DC, et al. Butyrylcholinesterase in the life cycle ot amyloid plaques. Ann Neurol 1997; 42 (6): 909-18
21. 21. Parnetti L, Senin U, Mecocci P. Congitive enhancement therapy for Alzheimer's disease: the way forward. Drugs 1997 May; 53: 752-68
22. 22. Relkin N, Orazem J, McRae T. The effect of concomitant donepezil and estrogen treatment on the cognitive performance of women with Alzheimer's disease [abstract]. Neurology 1999 Apr; 52 Suppl. 2: A397-8
23. 23. Doody RS. Clinical benefits of a new piperidine-class AChE inhibitor. Eur Neuropsychopharmacol 1999 Apr; 9 Suppl. 2: S69-77
24. 24. Whitehouse PJ. Donepezil: a viewpoint. Drugs Aging 1997 Mar; 10: 240-1
25. 25. Galli A, Mori F, Benini L, et al. Acetylcholinesterase protection and the anti-diisopropylfluorophosphate efficacy of E2020. Eur J Pharmacol Environ Toxicol Pharmacol 1994 Apr 4; 270: 189-93
26. 26. Nochi S, Asakawa N, Sato T. Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020). Biol Pharm Bull 1995 Aug; 18: 1145-7
27. 27. Kojima J, Nakajima K, Ochiai M, et al. Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia. Methods Find Exp Clin Pharmacol 1997 May; 19: 245-51
28. 28. Mimori Y, Nakamura S, Yukawa M. Abnormalities of acetylcholinesterase in Alzheimer's disease with special reference to effect of acetylcholinesterase inhibitor. Behav Brain Res 1997 Feb; 83: 25-30
29. 29. Hang Cheng D, Can Tang X. Comparative studies of huperzine A, E2020, and tacrine on behaviour and cholinesterase activities. Pharmacol Biochem Behav 1998; 60 (2): 377-86
30. 30. Sugimoto H, Iimura Y, Yamanishi Y, et al. Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine hydrochloride (E2020) and related compounds. Bioorganic Med Chem Lett 1992; 2 (8): 871-6
31. 31. Yamanishi Y, Ogura H, Kosasa T, et al. Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase in aged rats [abstract]. Eur J Pharmacol 1990 Jul 5; 183: 1935
32. 32. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998 May 11; 158: 1021-31
33. 33. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998 Jan; 50: 136-45
34. 34. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of US multicentre open label extension study. Eur Neuropsychopharmacol 1998 Feb; 8: 67-75
35. 35. Tiseo PJ, Rogers SL, Friedhoff L. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol 1998 Nov; 46 Suppl. 1: 13-8
36. 36. Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol 1998 Nov; 46 Suppl. 1: 1-6
37. 37. Kawashima K, Sato A, Yoshizawa M, et al. Effects of the centrally acting cholinesterase inhibitors tetrahydroamino-acridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats. Naunyn Schmiedebergs Arch Pharmacol 1994 Nov; 350: 523-8
38. 38. Giacobini E, Zhu X-D, Williams E, et al. The effect of the selective reversible acetylcholinesterasc inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology 1996 Feb; 35: 205-11
39. 3 antagonist thioperamide, in models of cognition and cholinergic function. Behav Pharmacol 1996 Nov; 7: 513-25
40. 40. Wanibuchi F, Nishida T, Yamashita H, et al. Characterization of a novel muscarinic receptor agonist, YM796: comparison with cholinesterase inhibitors in in vivo pharmacological studies. Eur J Pharmacol 1994 Nov 24; 265: 151-8
41. 41. Suzuki M, Yamaguchi T, Ozawa Y, et al. Effects of (-)-S-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro [4,5]decane L-tartrate monohydrate (YM796), a novel muscarinic agonist, on disturbance of passive avoidance learning behavior in drug-treated and senescence-accelerated mice. J Pharmacol Exp Ther 1995 Nov; 275: 728-36
42. 42. Wang T, Tang XC. Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine. E J Pharmacol 1998 May 22; 349: 137-42
43. 43. Braida D, Paladini E, Griffini P, et al. An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors. Eur J Pharmacol 1996 Apr 29; 302: 13-20
44. 44. Smith RD, Kistler MK, Cohen-Williams M, et al. Cholinergic improvement of a naturally-occurring memory deficit in the young rat. Brain Res 1996 Jan 22; 707: 13-21
45. 45. Rupniak NMJ, Tye SJ, Field MJ. Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys. Psychopharmacology 1997 Jun 11; 131: 406-10
46. 46. Mihara M, Ohnishi A, Tomono Y, et al. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 1993 May; 31: 223-9
47. 47. Ohnishi A, Mihara M, Kamakura H, et al. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J Clin Pharmacol 1993 Nov; 33: 1086-91
48. 48. Rogers SL, Cooper NM, Sukovaty R, et al. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 1998 Nov; 46 Suppl. 1: 7-12
49. 14C-donepezil in healthy volunteers: a single-dose study. Br J Clin Pharmacol 1998 Nov; 46 Suppl. 1: 19-24
50. 50. Tiseo PJ, Vargas R, Perdomo CA, et al. An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function. Br J Clin Pharmacol 1998 Nov; 46 Suppl. 1: 51-5
51. 51. Tiseo PJ, Foley K, Friedhoff LT. An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. Br J Clin Pharmacol 1998 Nov; 46 Suppl. 1: 56-60
52. 52. Aricept prescribing information. Eisai/Pfizer. USA, 1996
53. 53. Aricept prescribing information. Eisai/Pfizer. UK, 1997
54. 54. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998 Nov; 46 Suppl. 1: 25-9
55. 55. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998 Nov; 46 Suppl. 1: 30-4
56. 56. Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol 1998 Nov; 46 Suppl. 1: 45-50
57. 57. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and digoxin: assessment of pharmacokinetic changes. Br J Clin Pharmacol 1998 Nov; 46 Suppl. 1: 40-4
58. 58. Tiseo PJ, Foley K, Friedhoff LT. Concurrent administration of donepezil HCl and theophylline: assessment of pharmacokinetic changes following multiple dose administration in healthy volunteers. Br J Clin Pharmacol 1998 Nov; 46 Suppl. 1: 35-9
59. 59. Burns A, Rossor M, Hecker J, et al. The effeets of donepezil in Alzheimer's disease - results from a multinational trial. Dementia Geriatr Cogn Disord 1999 May-Jun; 10: 237-44
60. 60. Pratt RD, Geldmacher D, Perdomo CA. An evaluation of the long-term efficacy of donepezil in patients from a phase III clinical extension trial [abstract]. Neurology 1999 Apr; 52 Suppl. 2: 481-2
61. 61. Pfizer Inc. Clinical trial results show ARICEPT effective and well-tolerated for long-term treatment of Alzheimer's disease [online]. Pfizer Inc., 1999. Available from URL http://prnewswire.com [accessed 1999Aug 8]
62. 62. Matthews H, Korbey J, Wilkinson D, et al. Donepezil in the treatment of Alzheimer's disease: results from the first eighteen months of a study in clinical practice in the UK. Eur Neuropsychopharmacol 1999 Sept; 9 Suppl. 5: S327
63. 63. Mohs R, Doody R, Morris J, et al. Donepezil preserves functional status in Alzheimer's disease patients: results from a 1-year prospective placebo-controlled study. Eisai Inc./Eisai Co. Ltd., USA/Japan 1999 (Data on file)
64. 64. Wood S, Cummings JL. Measuring outcomes in Alzheimer's disease research: assessment of the effectiveness of interventions. Dis Manage Health Outcomes 1999 Jan; 5: 1-12
65. 65. Homma A, Imai Y, Hariguchi S, et al. Late phase II clinical study of acetylcholinesterase inhibitor E 2020 in patients with Alzheimer-type dementia: 8-weeks double-blind parallel study in two groups, 2 mg /day, 0.1 mg/day [in Japanese]. Rinsho Hyoka 1998; 26 (2): 185-207
66. 66. Homma A, Imai Y, Hariguchi S, et al. Late phase II clinical study of acetylcholinesterase inhibitor E 2020 in patients with Alzheimer-type dementia: 24-48-weeks double-blind, placebo-controlled study [in Japanese]. Rinsho Hyoka 1998; 26 (2): 209-31
67. 67. Homma A, Imai Y, Hariguchi S, et al. Late phase II clinical study of acetycholinesterase inhibitor E 2020 in patients with Alzheimer-type dementia: 12-weeks double-blind, placebo-controlled study, 3 mg/day, 5 mg/day [in Japanese]. Rinsho Hyoka 1998; 26 (2): 251-84
68. 68. McRae T, Orazem J. A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's disease (AD) [abstract]. J Am Geriatr Soc 1999 Sept; 47: S63
69. 69. Cummings JL, Katz IR, Tariot P, et al. Donepezil in the treatment of Alzheimer's disease in a nursing home population [abstract]. Neurology 1999; 52 Suppl. 2: A481
70. 70. Friedhoff LT, Rogers SL. Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease - results of a preliminary evaluation [abstract]. Neurology 1997; 48 (3) Suppl.: A 100
71. 71. Eisai/Pfizer. Aricept 3/5mg(donepezil hydrochloride) prescribing information. Japan, 1999
72. 72. Berg L, Miller JP, Baty J, et al. Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. Ann Neurol 1992; 31 (3): 242-9
73. 73. Winbald B, Engedal K, Soininen H, et al. Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one-year, double-blind trial in patients with mild to moderate Alzheimer's disease. Pfizer Inc. USA 1999 (Data on file)
74. 74. Robert PH, Lebert F, Goni S, et al. The impact of caregiver distress of donepezil treatment of patients with mild Alzheimer's disease [abstract]. American Psychiatric Association; 1999 Annual Meeting: New Research Program and Abstracts; 1999 May 15; Washington, DC: 221
75. 75. Gauthier S, Lussier I, TriAD Study Group. Donepezil treatment is associated with alleviation of caregiver burden in Alzheimer's disease: interim analysis from an open-label multicentre clinical trial [abstract]. Eur J Neurol 1999; 6 Suppl. 3: 116
76. 76. Rogers SL, Friedhoff LT. Donepezil is well tolerated at clinically effective doses for the treatment of Alzheimer's disease (AD) [abstract]. Eur Neuropsychopharmacol 1997 Sep; 7 Suppl. 2: S251
77. 77. Benesová O. Neuropathobiology of senile dementia and mechanism of action of nootropic drugs. Drugs Aging 1994 Apr; 4: 285-303
78. 78. Whitehouse PJ. Cholinesterase inhibitors in Alzheimer's disease: are they worth the cost? CNS Drugs 1999 Mar; 11: 167-73
79. 79. Eagger SA, Harvey RJ. Tacrine and other anticholinesterase drugs in dementia. Curr Opin Psychiatry 1995 Jul; 8: 264-7
80. 80. Burns A, Russell E, Page S. New drugs for Alzheimer's disease. Br J Psychiatry 1999 Jun; 174: 476-9
81. 81. Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging 1994 Jun; 4: 510-40
82. 82. Kaufer D, Catt K, Pollock B, et al. Assessing the effects of donepezil in Alzheimer's patients and its impact on caregivers [abstract]. J Am Geriatr Soc 1998 Sep; 46: S66
83. 83. Lovestone S, Graham N, Howard R. Guidelines on drug treatments for Alzheimer's disease. Lancet 1997 Jul 26; 350: 232-3
84. 84. Doody R, Pratt R, Perdomo C. Donepezil: clinical results from a long-term phase III extension trial [abstract]. Eur J Neurol 1999; 6 Suppl. 3: 27
85. 85. Holmes C, Cairns N, Lantos P, et al. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 1999; 174: 45-50